Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 29;11(11):e007479. doi: 10.1136/jitc-2023-007479

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Clinical significance of TP53 status and E2F1 in patients with HCC. (A) Tumor tissues from patients with HCC were isolated and infiltrated CD8 (green), PD-L1 (red) and E2F1 (pink) were stained. (B–C) Comparison of IRS score of PD-L1 and CD8 between E2F1 low expression group and high expression groups in different TP53 statuses were shown. (D–G) OS of patients with HCC after surgery based on the TP53 statuses and level of E2F1 in HCC was evaluated by the Kaplan-Meier method. (H) Graphical summary of the bidirectional regulatory mechanisms of PD-L1 in HCC. HCC, hepatocellular carcinoma; IRS, Immune Reactive Score; mTOR, mammalian target of rapamycin; mTORC1, mammalian target of rapamycin complex 1; PD-1, programmed death 1; PD-L1, programmed death ligand 1; OS, overall survival; WT, wild-type.